MTVA Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -- compared to MetaVia's net margin of -34674.95%. MetaVia's return on equity of -- beat Cytokinetics's return on equity of --.

MetaVia has a consensus price target of --, signalling upside risk potential of 775.42%. On the other hand Cytokinetics has an analysts' consensus of $81.71 which suggests that it could grow by 73.29%. Given that MetaVia has higher upside potential than Cytokinetics, analysts believe MetaVia is more attractive than Cytokinetics.

MetaVia has a beta of -0.250, which suggesting that the stock is 125.025% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.368%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $463K. MetaVia's net income of -$5.7M is higher than Cytokinetics's net income of -$160.5M. Notably, MetaVia's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 1,567.08x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Dermata Therapeutics has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Dermata Therapeutics's return on equity of --.

MetaVia has a consensus price target of --, signalling upside risk potential of 775.42%. On the other hand Dermata Therapeutics has an analysts' consensus of $6.00 which suggests that it could grow by 347.76%. Given that MetaVia has higher upside potential than Dermata Therapeutics, analysts believe MetaVia is more attractive than Dermata Therapeutics.

MetaVia has a beta of -0.250, which suggesting that the stock is 125.025% less volatile than S&P 500. In comparison Dermata Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dermata Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Dermata Therapeutics pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Dermata Therapeutics quarterly revenues of --. MetaVia's net income of -$5.7M is lower than Dermata Therapeutics's net income of -$3.2M. Notably, MetaVia's price-to-earnings ratio is -- while Dermata Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus -- for Dermata Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -- compared to MetaVia's net margin of -1141.73%. MetaVia's return on equity of -- beat Ocugen's return on equity of -136.91%.

MetaVia has a consensus price target of --, signalling upside risk potential of 775.42%. On the other hand Ocugen has an analysts' consensus of -- which suggests that it could grow by 672.94%. Given that MetaVia has higher upside potential than Ocugen, analysts believe MetaVia is more attractive than Ocugen.

MetaVia has a beta of -0.250, which suggesting that the stock is 125.025% less volatile than S&P 500. In comparison Ocugen has a beta of 3.823, suggesting its more volatile than the S&P 500 by 282.261%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Ocugen quarterly revenues of $1.1M. MetaVia's net income of -$5.7M is higher than Ocugen's net income of -$13M. Notably, MetaVia's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 45.14x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

MetaVia has a consensus price target of --, signalling upside risk potential of 775.42%. On the other hand ZyVersa Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1769.16%. Given that ZyVersa Therapeutics has higher upside potential than MetaVia, analysts believe ZyVersa Therapeutics is more attractive than MetaVia.

MetaVia has a beta of -0.250, which suggesting that the stock is 125.025% less volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than ZyVersa Therapeutics quarterly revenues of --. MetaVia's net income of -$5.7M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, MetaVia's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.